Argenx
ARGX
#432
Rank
C$74.03 B
Marketcap
C$1,189
Share price
1.27%
Change (1 day)
32.02%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): C$1.34 Billion

According to Argenx 's latest financial reports the company's current earnings are C$3.60 Billion. In 2024 the company made an earning of C$0.11 Billion, an increase over its 2023 earnings that were of -C$0.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) C$1.34 B1043.6%
2024 C$0.11 B-127.97%
2023 -C$0.42 Billion-58.25%
2022 -C$1.01 Billion80.17%
2021 -C$0.56 Billion
2019 -C$0.28 Billion124.86%
2018 -C$0.13 Billion131.81%
2017 -C$52.6 Million
2015 -C$25.4 Million
2013 -C$15.37 Million